ABSTRACT
Lycopene, the main carotenoid found in tomatoes and tomato-based products, has been reported to be protective against several types of cancer. Assessment of changes in plasma concentration of carotenoids following ingestion of lycopene-rich food sources does not necessarily predict changes in lycopene concentration or distribution of its isomers in other body tissues. Our aim was to determine the relationship between concentrations of lycopene and other tomato carotenoids in human serum and body tissues after tomato-oleoresin supplementation. Tomato lycopene oleoresin (30 mg/d) or a placebo was administered for 1 to 7 weeks to seventy-five volunteers undergoing elective haemorrhoidectomy or peri-anal fistulotomy. Carotenoid concentration and isomer distribution in blood and in the surgically removed skin and adipose tissues was measured by HPLC. The serum concentration of lycopene increased after supplementation from 0.26 (SD 0.12) to 0.52 (SD 0.25) micromol/l (n 35; P<0.0001). In the placebo group (n 40), lycopene serum concentration did not change significantly. Serum lycopene concentration after treatment was 2.2-fold greater in the lycopene group than in the placebo group, a slightly higher ratio than that found in skin and adipose tissue (1.6- and 1.4-fold higher than the placebo, respectively). A significant correlation between serum and tissue concentrations was found for both beta-carotene and lycopene in the placebo group, whereas in the lycopene-supplemented group the correlation between serum and tissues remained the same for beta-carotene but for lycopene was weak. Lycopene supplementation did not significantly change the proportion of all-trans v. cis isomers in the serum and tissues, despite the fact that more than 90 % of the supplemented lycopene was in the all-trans form. These results show that tomato-oleoresin supplementation increases lycopene concentrations in serum and in adipose tissue and skin. The ability to increase lycopene levels in tissues is one of the prerequisites for using it as a food supplement with health benefits.
Subject(s)
Adipose Tissue/metabolism , Anticarcinogenic Agents/analysis , Carotenoids/analysis , Dietary Supplements , Plant Extracts/administration & dosage , Skin/metabolism , Solanum lycopersicum , Adult , Aged , Anticarcinogenic Agents/blood , Anticarcinogenic Agents/pharmacokinetics , Biological Availability , Carotenoids/blood , Carotenoids/pharmacokinetics , Chromatography, High Pressure Liquid , Female , Hemorrhoids/surgery , Humans , Lycopene , Male , Middle Aged , Rectal Fistula/surgery , alpha-Tocopherol/blood , beta Carotene/bloodABSTRACT
The biochemical mechanisms underlying the inhibitory effects of lycopene, the main tomato carotenoid, on the growth of cancer cells are largely unknown. It has been hypothesized that lycopene derivatives may act as ligands for a nuclear receptor in analogy to retinoic acid, the hormone derived from beta-carotene. The inhibition of human mammary cancer (MCF-7) cell growth and the transactivation of the retinoic acid receptor (RAR) reporter gene by synthetic acyclo-retinoic acid, the open chain analog of retinoic acid, was compared to the effects of lycopene and retinoic acid in the same systems. Acyclo-retinoic acid activated the DR-5 retinoic acid response element with a approximately 100-fold lower potency than retinoic acid. This effect was independent of cotransfection with the RARalpha receptor. Lycopene exhibited only very modest activity in this system. In contrast to the results from the transactivation studies, acyclo-retinoic acid, retinoic acid, and lycopene inhibited cell growth with a similar potency. Preincubation with each of the three compounds slowed down cell cycle progression from G1 to S phase. In summary, acyclo-retinoic acid inhibited cancer cell growth and interacted with RAR. However, it exhibited low affinity for RAR and a correspondingly low efficacy in activating this receptor, indicating that RAR does not mediate the growth inhibitory effect of the compound. In addition, the concentrations of acyclo-retinoic acid and of lycopene required for inducing inhibition of cell growth were similar, suggesting that acyclo-retinoic acid is unlikely to be the active metabolite of lycopene.
Subject(s)
Antineoplastic Agents/pharmacology , Carotenoids/pharmacology , Receptors, Retinoic Acid/metabolism , Retinoids/pharmacology , Tumor Suppressor Proteins , Breast Neoplasms , Cell Cycle/drug effects , Cell Cycle Proteins/metabolism , Cell Division/drug effects , Cyclin D1/metabolism , Cyclin-Dependent Kinase Inhibitor p21 , Cyclin-Dependent Kinase Inhibitor p27 , Cyclins/metabolism , Humans , Lycopene , Receptors, Retinoic Acid/drug effects , Tumor Cells, CulturedABSTRACT
Numerous studies have demonstrated the anticancer activity of the tomato carotenoid, lycopene. However, the molecular mechanism of this action remains unknown. Lycopene inhibition of human breast and endometrial cancer cell growth is associated with inhibition of cell cycle progression at the G(1) phase. In this study we determined the lycopene-mediated changes in the cell cycle machinery. Cells synchronized in the G(1) phase by serum deprivation were treated with lycopene or vehicle and restimulated with 5% serum. Lycopene treatment decreased serum-induced phosphorylation of the retinoblastoma protein and related pocket proteins. This effect was associated with reduced cyclin-dependent kinase (cdk4 and cdk2) activities with no alterations in CDK protein levels. Lycopene caused a decrease in cyclin D1 and D3 levels whereas cyclin E levels did not change. The CDK inhibitor p21(Cip1/Waf1) abundance was reduced while p27(Kip1) levels were unaltered in comparison to control cells. Serum stimulation of control cells resulted in reduction in the p27 content in the cyclin E--cdk2 complex and its accumulation in the cyclin D1--cdk4 complex. This change in distribution was largely prevented by lycopene treatment. These results suggest that lycopene inhibits cell cycle progression via reduction of the cyclin D level and retention of p27 in cyclin E--cdk2, thus leading to inhibition of G(1) CDK activities.
Subject(s)
Adenocarcinoma/pathology , Anticarcinogenic Agents/pharmacology , Breast Neoplasms/pathology , CDC2-CDC28 Kinases , Carotenoids/pharmacology , Cyclin E/metabolism , Cyclin-Dependent Kinases/metabolism , Cyclins/metabolism , Cyclins/physiology , Endometrial Neoplasms/pathology , G1 Phase/drug effects , Neoplasm Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , Proteins , Adenocarcinoma/metabolism , Breast Neoplasms/metabolism , Culture Media, Serum-Free/pharmacology , Cyclin D , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinase Inhibitor p21 , Endometrial Neoplasms/metabolism , Female , Fetal Blood/physiology , Humans , Lycopene , Macromolecular Substances , Nuclear Proteins/metabolism , Phosphoproteins/metabolism , Phosphorylation/drug effects , Protein Processing, Post-Translational/drug effects , Retinoblastoma Protein/metabolism , Retinoblastoma-Like Protein p107 , Retinoblastoma-Like Protein p130 , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolismABSTRACT
Carnosic acid, the polyphenolic diterpene derived from rosemary, is a strong dietary antioxidant that exhibits antimutagenic properties in bacteria and anticarcinogenic activity in various cell and animal models. In the present study, we show that carnosic acid (2.5-10 microM) inhibits proliferation of HL-60 and U937 human myeloid leukemia cells (half-maximal inhibitory concentration = 6-7 microM) without induction of apoptotic or necrotic cell death. Growth arrest occurred concomitantly with a transient cell cycle block in the G1 phase, which was accompanied by an increase in the immunodetectable levels of the universal cyclin-dependent kinase inhibitors p21WAFI and p27Kipl. Carnosic acid caused only a marginal induction of differentiation, as monitored by the capacity to generate superoxide radicals and the expression of cell surface antigens (CD11b and CD14) and receptors for the chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine. However, at low concentrations, this polyphenol substantially augmented (100- to 1,000-fold) the differentiating effects of 1,25-dihydroxyvitamin D3 and all-trans retinoic acid. Furthermore, such combinations of carnosic acid and any of these differentiation inducers synergistically inhibited proliferation and cell cycle progression. These results indicate that carnosic acid is capable of antiproliferative action in leukemic cells and can cooperate with other natural anticancer compounds in growth-inhibitory and differentiating effects.
Subject(s)
Calcitriol/pharmacology , Cell Differentiation/drug effects , Cell Division/drug effects , Diterpenes/pharmacology , Leukemia/pathology , Plant Extracts/pharmacology , Tretinoin/pharmacology , Abietanes , Antineoplastic Agents, Phytogenic , Apoptosis/drug effects , Cell Cycle/drug effects , Cell Cycle Proteins/metabolism , Cyclin-Dependent Kinase Inhibitor p21 , Cyclin-Dependent Kinase Inhibitor p27 , Cyclins/metabolism , Drug Interactions , Flow Cytometry , G1 Phase/drug effects , HL-60 Cells/pathology , Humans , Leukemia, Myeloid/pathology , Rosmarinus/chemistry , Tumor Cells, Cultured , Tumor Suppressor Proteins/metabolism , U937 Cells/pathologyABSTRACT
Recent studies have shown that high insulin-like growth factor I (IGF-I) blood level is a risk factor in breast and prostate cancer. The aim of this study was to determine whether the mitogenic activity of IGF-I in mammary cancer cells can be reduced by the dietary carotenoid lycopene. The anticancer activity of lycopene, the major tomato carotenoid, has been suggested by in vitro, in vivo, and epidemiological studies. Growth stimulation of MCF7 mammary cancer cells by IGF-I was markedly reduced by physiological concentrations of lycopene. The inhibitory effects of lycopene on MCF7 cell growth were not accompanied by apoptotic or necrotic cell death, as determined by annexin V binding to plasma membrane and propidium iodide staining of nuclei in unfixed cells. Lycopene treatment markedly reduced the IGF-I stimulation of tyrosine phosphorylation of insulin receptor substrate 1 and binding capacity of the AP-1 transcription complex. These effects were not associated with changes in the number or affinity of IGF-I receptors, but with an increase in membrane-associated IGF-binding proteins, which were previously shown in different cancer cells to negatively regulate IGF-I receptor activation. The inhibitory effect of lycopene on IGF signaling was associated with suppression of IGF-stimulated cell cycle progression of serum-starved, synchronized cells. Moreover, in cells synchronized by mimosine treatment, lycopene delayed cell cycle progression after release from the mimosine block. Collectively, the above data suggest that the inhibitory effects of lycopene on MCF7 cell growth are not due to the toxicity of the carotenoid but, rather, to interference in IGF-I receptor signaling and cell cycle progression.
Subject(s)
Anticarcinogenic Agents/pharmacology , Breast Neoplasms/metabolism , Carotenoids/pharmacology , Cell Cycle/drug effects , Insulin-Like Growth Factor I/metabolism , Signal Transduction/drug effects , Breast Neoplasms/pathology , Cell Death/drug effects , Cell Division , Coloring Agents , DNA/analysis , DNA/biosynthesis , Humans , Insulin-Like Growth Factor I/pharmacology , Lycopene , Propidium , Tumor Cells, CulturedABSTRACT
The diverse health benefit effects of garlic include its anticancer activity. However, very little is known about such activity of isolated garlic compounds, among which allicin (the major ingredient of crushed garlic) has been the least studied. The aim of this work was to determine whether pure allicin exhibits the antiproliferative effect reported for garlic in in vitro models. Allicin, but not its precursor alliin, inhibited proliferation of human mammary (MCF-7), endometrial (Ishikawa), and colon (HT-29) cancer cells (50% inhibitory concentration = 10-25 microM). Two of three tested primary lines of human fibroblasts displayed a similar response to allicin (50% inhibitory concentration = 16-40 microM), whereas the third line was almost unaffected by this compound. The pure allicin and water extract of garlic powder with equivalent allicin concentrations displayed a similar potency, suggesting that allicin is responsible for the antiproliferative effect of the extract. The growth inhibition was accompanied by accumulation of cells in the G0/G1 and G2/M phases of the cell cycle (MCF-7 cells) and not by a significant increase in cell death. Allicin caused a transient drop in the intracellular glutathione (GSH) level, the magnitude and kinetics of which significantly varied depending on cell type. The extent of the decrease in GSH levels correlated well (r = 0.75) with the growth inhibitory activity of allicin. On the basis of these findings, we suggest that allicin plays a major role in the antiproliferative effect of water-soluble garlic preparations and that this effect may be attributed to the ability of allicin to transiently deplete the intracellular GSH level.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Cell Transformation, Neoplastic/drug effects , Garlic/chemistry , Plants, Medicinal , Sulfinic Acids/pharmacology , Cell Cycle/drug effects , Cell Death/drug effects , Cell Division/drug effects , Colonic Neoplasms/pathology , Disulfides , Dose-Response Relationship, Drug , Endometrial Neoplasms/pathology , Female , Fibroblasts/cytology , Fibroblasts/drug effects , Glutathione/metabolism , Humans , Kinetics , Male , Mammary Neoplasms, Animal/pathology , Plant Extracts , Tumor Cells, CulturedABSTRACT
Lycopene, the major tomato carotenoid, has been found to inhibit proliferation of several types of cancer cells, including those of breast, lung, and endometrium. By extending the work to the HL-60 promyelocytic leukemia cell line, we aimed to evaluate some mechanistic aspects of this effect. Particularly, the possibility was examined that the antiproliferative action of the carotenoid is associated with induction of cell differentiation. Lycopene treatment resulted in a concentration-dependent reduction in HL-60 cell growth as measured by [3H]thymidine incorporation and cell counting. This effect was accompanied by inhibition of cell cycle progression in the G0/G1 phase as measured by flow cytometry. Lycopene alone induced cell differentiation as measured by phorbol ester-dependent reduction of nitro blue tetrazolium and expression of the cell surface antigen CD14. Results of several recent intervention studies with beta-carotene, which have revealed no beneficial effects of this carotenoid, suggest that a single dietary component cannot explain the anticancer effect of diets rich in vegetables and fruits. Thus another goal of our study was to examine whether lycopene has the ability to synergize with other natural anticancer compounds, such as 1,25-dihydroxyvitamin D3, which when used alone are therapeutically active only at high and toxic concentrations. The combination of low concentrations of lycopene with 1,25-dihydroxyvitamin D3 exhibited a synergistic effect on cell proliferation and differentiation and an additive effect on cell cycle progression. Such synergistic antiproliferative and differentiating effects of lycopene and other compounds found in the diet and in plasma may suggest the inclusion of the carotenoid in the diet as a cancer-preventive measure.
Subject(s)
Anticarcinogenic Agents/pharmacology , Carotenoids/pharmacology , HL-60 Cells/drug effects , Leukemia, Promyelocytic, Acute/pathology , Vitamin D/analogs & derivatives , Cell Cycle/drug effects , Cell Differentiation/drug effects , Cell Division/drug effects , Dose-Response Relationship, Drug , Flow Cytometry , Humans , Leukemia, Promyelocytic, Acute/prevention & control , Lycopene , Vitamin D/pharmacologyABSTRACT
It has been suggested that adjunctive growth hormone (GH) therapy improves ovarian response and in vitro fertilization (IVF) outcome in specific groups of patients. The correlation between insulin-like growth factor (IGF) and GH is well established. The aim of this study was to determine whether changes in plasma GH correlate with IGF blood levels in patients during IVF treatment. Thirty-six women undergoing IVF and embryo transfer (ET) were examined. Ovarian stimulation was carried out by gonadotropin-releasing hormone agonists (GnRHa) and gonadotropins. Blood was drawn at the early and late follicular phase, on the day of human chorionic gonadotropin (hCG) injection and at the mid- and the late luteal phases. The samples were assayed for IGF-I, IGF-II, IGF-binding protein-3 (IGF BP-3), GH and estradiol. According to the IGF-I and GH plasma levels, patients were divided into three major groups: Group I consisted of patients in whom peak levels of GH reached more than 4 ng/ml and IGF-I decreased significantly. In this group, estradiol levels were 1863 +/- 149 pg/ml. Group II consisted of patients in whom peak blood GH levels did not exceed 2.5 ng/ml and the IGF-I level remained unchanged. In this group estradiol levels were 630 +/- 57 pg/ml. Group III consisted of patients in whom blood GH levels were low and remained unchanged while estradiol levels were 1600 +/- 420 pg/ml. In this group no significant increase in IGF-levels were observed. There was no significant change in the levels of either IGF-II or IGF BP-3 in any of the groups. We can conclude that (1) there is a negative correlation between GH and IGF-I plasma levels in patients undergoing controlled ovarian hyperstimulation (COH)-IVF, when levels of estradiol and GH are elevated; (2) plasma levels of IGF-I under ovarian hyperstimulation are probably regulated by a multifactorial system; and (3) no correlation was found between the plasma levels of IGF-I and those of IGF-II and IGF BP-3 in all patient groups.
Subject(s)
Embryo Transfer , Fertilization in Vitro , Human Growth Hormone/blood , Insulin-Like Growth Factor I/metabolism , Adult , Chorionic Gonadotropin/administration & dosage , Estradiol/blood , Female , Follicular Phase , Humans , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor II/metabolism , Luteal Phase , Ovulation Induction , PregnancyABSTRACT
The function of cell surface-associated insulin-like growth factor-binding proteins (IGFBPs) is controversial. Both inhibition and facilitation of IGF action as well as IGF-independent effects have been reported. We examined the influence of endogenous cell surface-associated IGFBPs on IGF-I receptor (IGF-IR) function in Ishikawa endometrial cancer cells by comparing the effects of IGF-I and its truncated analog des-(1-3)-IGF-I on several components of the IGF-IR signal transduction pathway in the absence of significant amounts of soluble IGFBPs. IGF-I and des-(1-3)-IGF-I are known to have similar affinities for IGF-IR, although the affinity of des-(1-3)-IGF-I for IGFBPs is greatly reduced. Here we show that the two ligands were equipotent not only in IGF-IR binding but also in receptor activation in NIH 3T3 cells overexpressing IGF-IR and possessing a relatively small number of cell surface-associated IGFBPs. In contrast, des-(1-3)-IGF-I manifested a remarkably higher potency as compared with IGF-I in inducing short and middle term cellular responses in IGF-IR-transfected Ishikawa endometrial cancer cells possessing a high number of both the receptor and the cell membrane-bound IGFBP-3. Thus, this difference in the effects of IGF-I and des-(1-3)-IGF-I can be attributed to the attenuation of IGF-I-mediated IGF-IR signaling by membrane-bound IGFBP-3.
Subject(s)
Endometrial Neoplasms/physiopathology , Insulin-Like Growth Factor Binding Protein 3/physiology , Insulin-Like Growth Factor I/antagonists & inhibitors , Membrane Proteins/physiology , Receptor, IGF Type 1/physiology , 3T3 Cells , Animals , Endometrial Neoplasms/pathology , Female , Humans , Insulin-Like Growth Factor I/metabolism , Mice , Phosphorylation , Tyrosine/metabolismABSTRACT
Consumption of carotenoids has frequently been inversely correlated with cancer incidence. In this report we used the 7,12-dimethyl-benz[a]anthracene (DMBA)-induced rat mammary tumor model to compare the effect of lycopene-enriched tomato oleoresin on the initiation and progression of these tumors with that of beta-carotene. Rats were injected i.p. with lycopene-enriched tomato oleoresin or beta-carotene (10 mg/kg, twice per week) for 2 weeks prior to tumor induction by DMBA and for an additional 16 weeks after carcinogen administration. HPLC analysis of carotenoids extracted from several tissues showed that both carotenoids were absorbed into blood, liver, mammary gland, and mammary tumors. The tomato oleoresin-treated rats developed significantly fewer tumors, and the tumor area was smaller than that of the unsupplemented rats. Rats receiving beta-carotene showed no protection against the development of mammary cancer.
Subject(s)
Anticarcinogenic Agents/therapeutic use , Antineoplastic Agents, Phytogenic/therapeutic use , Carotenoids/therapeutic use , Mammary Neoplasms, Experimental/prevention & control , 9,10-Dimethyl-1,2-benzanthracene , Animals , Anticarcinogenic Agents/blood , Antineoplastic Agents, Phytogenic/blood , Carotenoids/blood , Drug Screening Assays, Antitumor , Female , Lycopene , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/drug therapy , Plant Extracts/therapeutic use , Rats , Rats, Sprague-Dawley , beta Carotene/blood , beta Carotene/therapeutic useABSTRACT
A significant increase in endometrial cancer incidence in tamoxifen-treated breast cancer patients has been reported in many recent studies. The major growth stimulators of endometrial tumors are estrogens, but paradoxically, tamoxifen, a known antiestrogen, also stimulates their growth. The mode of action of estrogen can be partially explained by the modulation of insulin-like growth factor (IGF) autocrine or paracrine action. The purpose of the present study was to examine the involvement of the IGF system in the tamoxifen-stimulated growth of Ishikawa endometrial cancer cells by quantitating the IGF-I receptors and their phosphorylation, as well as membrane associated and secreted IGF-binding proteins (IGFBPs). Tamoxifen did not affect the number or affinity of IGF-I receptors. On the other hand, tamoxifen, similar to estradiol, increased IGF-I-stimulated tyrosine phosphorylation of cellular substrates. In contrast, in MCF-7 mammary cancer cells, tamoxifen reduced IGF-induced tyrosine phosphorylation in the presence of estradiol. The pure antiestrogen LY156758 did not affect Ishikawa basal cell growth but inhibited estradiol- and tamoxifen-induced growth. Growth inhibition by LY156758 of tamoxifen and estradiol-stimulated cells was accompanied by a corresponding inhibition of IGF-stimulated tyrosine phosphorylation. Tamoxifen caused a 3-fold decrease in membrane-associated IGFBPs. Moreover, a reduction in soluble IGFBPs was also observed, making the IGF peptides more available to the receptors. A parallel decrease in IGFBP-3 mRNA was also detected. These experiments suggest that tamoxifen, like estradiol, directly sensitizes endometrial cancer cells to the effects of IGFs that act through the type I receptor. Furthermore, the decrease in IGFBPs and the increase in tyrosine phosphorylation in the presence of tamoxifen provides a molecular mechanism that accounts for the uterotropic effects that are seen with tamoxifen therapy.
Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Endometrial Neoplasms/pathology , Insulin-Like Growth Factor Binding Proteins/metabolism , Insulin-Like Growth Factor I/pharmacology , Tamoxifen/adverse effects , Cell Division/drug effects , Endometrial Neoplasms/metabolism , Estrogen Antagonists/pharmacology , Female , Humans , Phosphorylation , Piperidines/pharmacology , Raloxifene Hydrochloride , Receptor, IGF Type 1/metabolism , Tumor Cells, Cultured , Tyrosine/metabolismABSTRACT
OBJECTIVE: The purpose of the present study was to determine the amniotic fluid and maternal plasma concentrations of cortisol and progesterone in nonlaboring women at term and to compare them to those in women with active labor at term. STUDY DESIGN: A prospective, cross-sectional study. Soroka Medical Center of Kupat Holim, Faculty of Health Sciences, Ben-Gurion University of the Negro, Beer-Sheva, Israel. Thirty-five healthy women with normal term pregnancies were classified according to labor status into two groups: group A (16 women with spontaneous, active labor at term) and group B (19 women not in labor). RESULTS: We found a significant increase in the median concentration of plasma cortisol in women at term in active labor in comparison to those not in labor. In addition, the median concentration of cortisol in amniotic fluid in women in labor was also significantly higher than that in women not in labor. In contrast, no significant changes in median maternal plasma or amniotic fluid progesterone concentrations were detected between the groups. CONCLUSION: Human parturition is associated with a significant increase in the concentration of cortisol in both maternal plasma and amniotic fluid. These findings suggest that cortisol plays an important but still-undetermined role in human parturition.
Subject(s)
Amniotic Fluid/chemistry , Hydrocortisone/analysis , Labor, Obstetric/blood , Pregnancy Trimester, Third/blood , Progesterone/analysis , Adult , Cesarean Section , Cross-Sectional Studies , Female , Humans , Pregnancy , Prospective StudiesABSTRACT
Detergent-mediated activation of the phagocyte superoxide-generating NADPH oxidase requires the participation of at least four proteins: the membrane-bound heterodimeric cytochrome b558 and three cytosolic components, p47-phox, p67-phox and a Rac1/Rac2 protein. Peptides corresponding to sequences of different subunits of NADPH oxidase have been used as probes of the mechanism and sequence of assembly of the active complex. In the present study effects of mastoparans on activation of NADPH oxidase were investigated. Mastoparans are wasp venom cationic amphiphilic tetradecapeptides capable of modulation of various cellular activities. Natural mastoparans, as well as several synthetic mastoparan analogues, unrelated to oxidase components, blocked activation of the oxidase in the cell-free system (EC50 = 1.5 microM) and in guanosine 5'-[gamma-thio]triphosphate (GTP[S])/ATP-stimulated neutrophils permeabilized with streptolysin O. In the cell-free system the effect was not relieved by raising the detergent concentration and could not be ascribed to changes in critical micellar concentration values of the activating SDS or arachidonate. Chromatography of neutrophil cytosol on an immobilized mastoparan column suggested interaction of cytosolic p47-phox and p67-phox with the peptide. In spite of this interaction mastoparan did not interfere with translocation of p47-phox and p67-phox to the cell membranes.
Subject(s)
NADH, NADPH Oxidoreductases/blood , Neutrophils/enzymology , Peptides/pharmacology , Wasp Venoms/pharmacology , Amino Acid Sequence , Bacterial Proteins , Cell Membrane Permeability , Cell-Free System , Cytochrome b Group/blood , Cytosol/metabolism , Enzyme Activation , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Humans , Intercellular Signaling Peptides and Proteins , Kinetics , Macromolecular Substances , Molecular Sequence Data , NADH, NADPH Oxidoreductases/biosynthesis , NADPH Dehydrogenase/blood , NADPH Oxidases , Peptides/chemistry , Phosphoproteins/blood , Protein Processing, Post-Translational , Streptolysins , Structure-Activity Relationship , Wasp Venoms/chemistryABSTRACT
Insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins (IGFBPs) were examined in Ishikawa endometrial cancer cells. Our findings suggest that about 95% of [125I]IGF-I is bound to membrane-associated IGFBPs rather than to IGF-I receptors. Specifically, [125I]IGF-I binding to cell membranes could be completely displaced by cold IGF-I or IGF-II, but not by insulin, suggesting that binding was primarily due to IGFBPs. This was confirmed by using [125I]des-(1-3)IGF-I as the ligand. Des-(1-3) IGF-I binds with high affinity to IGF-I receptors, but with markedly lower affinity to IGFBPs. [125I]Des-(1-3)IGF-I bound to Ishikawa cells was displaced by IGF-I, IGF-II, and insulin. These results suggest that measuring IGF-I receptor levels using labeled IGF-I may be misleading. Accordingly, we evaluated the differential binding of [125I]IGF-I and [125I]des-(1-3)IGF-I to study the involvement of the IGF system in the stimulation of Ishikawa cell growth by estradiol. IGF-I stimulates Ishikawa cell proliferation, but at low concentrations, and this stimulation is largely dependent on the presence of estradiol. Estradiol caused a 2.5-fold increase in IGF-I receptor levels. Moreover, estradiol reduced soluble IGFBP levels, presumably increasing the availability of IGFs for their receptors. This elevation in IGF-I receptor levels and the decrease in IGFBP levels were accompanied by a 3.5-fold increase in IGF-I receptor messenger RNA and a 2.5-fold decrease in IGFBP messenger RNAs. These experiments suggest that estradiol sensitizes endometrial cancer cells to the effects of IGFs by simultaneously elevating receptor levels and decreasing (potentially inhibitory) IGFBP levels.
Subject(s)
Carrier Proteins/metabolism , Endometrial Neoplasms/metabolism , Estradiol/pharmacology , Receptor, IGF Type 1/drug effects , Receptor, IGF Type 1/metabolism , Somatomedins/metabolism , Binding, Competitive , Cell Membrane/metabolism , Culture Media, Conditioned , Drug Synergism , Estradiol/administration & dosage , Female , Gene Expression , Humans , Insulin-Like Growth Factor I/administration & dosage , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor I/pharmacology , Kinetics , Peptide Fragments/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptor, IGF Type 1/genetics , Tumor Cells, CulturedABSTRACT
This study was undertaken to investigate a possible relationship between endogenous secretion of growth hormone (GH) during ovarian stimulation and treatment outcome in patients undergoing in-vitro fertilization (IVF) and embryo transfer. Plasma samples obtained from 19 women who had successfully completed all stages of IVF/embryo transfer were analysed retrospectively. Based on the increase in GH during treatment, 11 GH responders and eight GH non-responders were identified. Mean daily GH concentrations for the GH responders and GH non-responders were 3.5 +/- 1.8 and 1.8 +/- 0.8, 5.4 +/- 2.3 and 0.5 +/- 0.2, and 9.0 +/- 1.9 and 0.7 +/- 0.1 ng/ml (P < 0.05) for days 10, 11 and 12 respectively. Plasma insulin-like growth factor-I slightly increased with treatment in both groups. No significant difference between these groups was found in relation to treatment duration, number of human menopausal gonadotrophin ampoules used, oestradiol peak values, and number of oocytes retrieved or fertilization rate. Seven of the 11 GH responder women conceived in comparison with one pregnancy among eight GH non-responder patients (P < 0.05). In view of the absence of differences in the clinical and laboratory parameters, we suggest that the occurrence of pregnancies among GH responder patients might be related to a positive local effect of GH or its mediators on uterine receptivity at the time of nidation.
Subject(s)
Growth Hormone/blood , Reproductive Techniques , Adult , Embryo Implantation/physiology , Embryo Transfer , Estradiol/blood , Female , Fertilization in Vitro , Humans , Infertility, Female/blood , Infertility, Female/therapy , Insulin-Like Growth Factor I/metabolism , Menotropins/administration & dosage , Ovulation Induction , Pregnancy , Retrospective StudiesABSTRACT
The antiproliferative properties of lycopene, the major tomato carotenoid, were compared with those of alpha- and beta-carotene. Lycopene, delivered in cell culture medium from stock solutions in tetrahydrofuran, strongly inhibited proliferation of endometrial (Ishikawa), mammary (MCF-7), and lung (NCI-H226) human cancer cells with half-maximal inhibitory concentration of 1-2 microM; alpha- and beta-carotene were far less effective inhibitors. For example, in Ishikawa cells, a 4-fold higher concentration of alpha-carotene or a 10-fold higher concentration of beta-carotene was needed for the same order of growth suppression. The inhibitory effect of lycopene was detected after 24 hours of incubation, and it was maintained for at least three days. In contrast to cancer cells, human fibroblasts were less sensitive to lycopene, and the cells gradually escaped growth inhibition over time. In addition to its inhibitory effect on basal endometrial cancer cell proliferation, lycopene also suppressed insulin-like growth factor-I-stimulated growth. Insulin-like growth factors are major autocrine/paracrine regulators of mammary and endometrial cancer cell growth. Therefore, lycopene interference in this major autocrine/paracrine system may open new avenues for research on the role of lycopene in the regulation of endometrial cancer and other tumors.
Subject(s)
Anticarcinogenic Agents/pharmacology , Carotenoids/pharmacology , Cell Division/drug effects , Anticarcinogenic Agents/administration & dosage , Breast Neoplasms/pathology , Carotenoids/administration & dosage , DNA/biosynthesis , Dose-Response Relationship, Drug , Endometrial Neoplasms/pathology , Female , Humans , Insulin-Like Growth Factor I/pharmacology , Lung Neoplasms/pathology , Lycopene , Tumor Cells, Cultured , beta CaroteneABSTRACT
The involvement of the IGF system in the growth regulation of hormone-dependent (e.g. endometrial and breast) cancer cells was studied. We chose two opposing effects of tamoxifen: the paradoxical stimulation of Ishikawa endometrial cancer cells growth and its inhibitory effect on MCF-7 mammary cancer cells. The results clearly confirm our working hypothesis that the IGF system is involved in growth regulation of these cancer cells irrespective of the direction of the drug effect. The following parameters of the IGFs system were studied: IGF-I receptors, IGF-I stimulated protein tyrosine phosphorylation, and membrane-associated and secreted IGF-binding proteins (IGFBPs). In Ishikawa cells, tamoxifen, similar to estradiol, increased IGF-I stimulated tyrosine phosphorylation of cellular substrates in accordance with its effect on cell growth. This effect of tamoxifen was inverted in MCF-7 cells. Tamoxifen did not affect the number or affinity of IGF-I receptors in both Ishikawa and MCF-7 cells, however, it caused a three-fold decrease in membrane-associated IGFBPs in the endometrial cells but an increase in these proteins in breast cancer cells. Similar but much less pronounced changes in soluble IGFBPs were observed. Our results indicate that the opposing growth effects of tamoxifen an endometrial and mammary cancer cells are associated with modulation of the IGF system components, mainly with reciprocal changes in membrane-associated IGFBPs.
Subject(s)
Breast Neoplasms/pathology , Endometrium/drug effects , Somatomedins/pharmacology , Tamoxifen/pharmacology , Cell Division/drug effects , Cell Membrane/metabolism , Endometrium/cytology , Estradiol/pharmacology , Female , Humans , Insulin-Like Growth Factor Binding Proteins/metabolism , Protein-Tyrosine Kinases/metabolism , Receptor, IGF Type 1/metabolism , Tumor Cells, CulturedABSTRACT
OBJECTIVE: Our objective was to study the direct action of the gonadotropin-releasing hormone antagonist SB-75 and the agonist buserelin on the proliferation of endometrial cancer cells. STUDY DESIGN: Two human endometrial cell lines that differ in histologic subtype and estrogen receptor content were treated with gonadotropin-releasing hormone analog. We measured the number of viable cells, cell cycle parameters, and apoptotic processes. RESULTS: Growth of the Ishikawa cells was inhibited by SB-75 in a dose-dependent manner. 17 beta-Estradiol partially abolished the inhibitory effect of SB-75. The growth of the HEC-1A cells was not affected by the antagonist. Neither endometrial cancer cell line showed significant sensitivity to the agonist buserelin. Tenfold concentration of the gonadotropin-releasing hormone agonist did not abolish the inhibitory effect of the antagonist on cell growth. The growth inhibition was not associated with any change in cell cycle parameters but was associated with an induction of apoptosis. CONCLUSION: The gonadotropin-releasing hormone antagonist SB-75 directly inhibits the growth of some human endometrial cancer cells and thus may be suitable for the treatment of endometrial tumors.
Subject(s)
Adenocarcinoma, Papillary/drug therapy , Apoptosis/drug effects , Endometrial Neoplasms/drug therapy , Gonadotropin-Releasing Hormone/analogs & derivatives , Gonadotropin-Releasing Hormone/antagonists & inhibitors , Adenocarcinoma, Papillary/chemistry , Adenocarcinoma, Papillary/pathology , Aged , Apoptosis/physiology , Buserelin/pharmacology , Buserelin/therapeutic use , Cell Cycle/drug effects , Cell Division/drug effects , DNA, Neoplasm/analysis , DNA, Neoplasm/isolation & purification , Dose-Response Relationship, Drug , Electrophoresis, Agar Gel , Endometrial Neoplasms/chemistry , Endometrial Neoplasms/pathology , Estradiol/pharmacology , Female , Flow Cytometry , Gonadotropin-Releasing Hormone/pharmacology , Gonadotropin-Releasing Hormone/therapeutic use , Humans , Receptors, Estrogen/analysis , Time Factors , Tumor Cells, CulturedABSTRACT
Mastoparan (MP), a wasp venom peptide, is known both to interact with G-proteins and to alter membrane structure and function. To determine the structural requirements for these two aspects of MP action, we constructed several analogs of the peptide and characterized them using Swiss 3T3 cell membranes. The effects of these peptides were measured on: i) G-protein-mediated stimulation of phospholipase-C activity by GTP gamma S and bombesin and ii) the membrane enzyme activities, calcium-activated phospholipase-C and Na,K-ATPase. MP strongly inhibited all the above activities and caused membrane permeabilization. Substitution of one Lys residue by Gly at either the N- or C-terminal of the MP molecule resulted in peptides which selectively inhibited G-protein stimulated phospholipase-C with no or very slight membrane-perturbing effects. Introduction of additional Lys residues to MP led to the opposite effect. Thus, G-protein modulating and membrane disrupting actions of MP appear to be not necessarily linked, and may be separated.
Subject(s)
GTP-Binding Proteins/metabolism , Oligopeptides/pharmacology , Peptide Fragments/pharmacology , Wasp Venoms/pharmacology , 3T3 Cells , Amino Acid Sequence , Animals , Bombesin/pharmacology , Cell Membrane/drug effects , Cell Membrane/metabolism , GTP-Binding Proteins/drug effects , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Intercellular Signaling Peptides and Proteins , Kinetics , Mice , Molecular Sequence Data , Oligopeptides/chemical synthesis , Peptide Fragments/chemical synthesis , Peptides , Sodium-Potassium-Exchanging ATPase/metabolism , Structure-Activity Relationship , Type C Phospholipases/metabolismABSTRACT
The involvement of IGFs in growth regulation of the Ishikawa endometrial tumor cell line and the possible interference of LH-RH analogues with a potential autocrine or paracrine loop involving IGFs was evaluated. The mitogenic effects of IGF-I, IGF-II, and insulin were compared. IGF-I was found to be 3-fold more potent than IGF-II and 30-fold more potent than insulin, suggesting that the effects of these growth factors are mediated by the IGF-I receptor. Ishikawa endometrial cancer cells secrete IGF-II, but not IGF-I, and insulin (1 microM) stimulates IGF-II release. The LH-RH antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6, D-Ala10]-GnRH (SB-75, CETRORELIX) inhibited basal and IGF-induced growth. Moreover, this antagonist almost completely inhibited IGF-II release from Ishikawa cells, while having no significant effect on the number or affinity of IGF-I binding sites. Inhibition of IGF-II release occurred at a lower SB-75 concentration than that needed for a reduction in cell number. The ED50 of SB-75 for IGF-II release was 0.3 microM as compared to 1.5 microns concentration which is required for reduction in cell number, suggesting that inhibition of growth factor release precedes cell growth inhibition. We conclude that the LH-RH antagonist SB-75 can inhibit the growth of endometrial cancer cells by interfering with the autocrine action of IGF-II and also by directly inhibiting the growth-stimulatory effects of IGFs, probably through effects on a post-receptor mechanism.